BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Lifted to “Strong-Buy” by Wall Street Zen

Posted by George Bondi on Oct 25th, 2026

Wall Street Zen upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Several other research analysts have also commented on the stock. Weiss Ratings lowered shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. JPMorgan Chase & Co. upped their target price on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 30th. Cantor Fitzgerald upped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th. Wedbush reduced their target price on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $19.44.

Get Our Latest Report on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $7.65 on Friday. The business has a 50-day moving average of $8.79 and a 200 day moving average of $9.10. BioCryst Pharmaceuticals has a 12 month low of $6.23 and a 12 month high of $11.22. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -5.10 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. BioCryst Pharmaceuticals’s revenue was up 33.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.15 EPS. Equities research analysts anticipate that BioCryst Pharmaceuticals will post -2.28 earnings per share for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Sterling Capital Management LLC raised its holdings in BioCryst Pharmaceuticals by 1,373.8% in the third quarter. Sterling Capital Management LLC now owns 12,056 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 11,238 shares in the last quarter. Inspire Investing LLC grew its holdings in BioCryst Pharmaceuticals by 426.1% during the 3rd quarter. Inspire Investing LLC now owns 362,878 shares of the biotechnology company’s stock worth $3,023,000 after acquiring an additional 293,899 shares in the last quarter. Bender Robert & Associates acquired a new position in BioCryst Pharmaceuticals during the 3rd quarter worth approximately $198,000. SteelPeak Wealth LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $114,000. Finally, Assenagon Asset Management S.A. increased its position in shares of BioCryst Pharmaceuticals by 27.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 449,082 shares of the biotechnology company’s stock valued at $3,741,000 after purchasing an additional 96,038 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

(Get Free Report)

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.